Half-Year Review of Inventiva’s Liquidity Contract with Kepler
Cheuvreux
Daix (France), Long Island City (New York,
United States), July 21, 2022 – Inventiva (Euronext Paris
and Nasdaq: IVA), a clinical-stage biopharmaceutical company
focused on the development of oral small molecule therapies for the
treatment of NASH and other diseases with significant unmet medical
needs, today announced the half-year report of its liquidity
contract with Kepler Cheuvreux.
Under the liquidity contract granted to Kepler
Cheuvreux by Inventiva, the following resources were available in
the liquidity account as of June 30, 2021:
- Cash: € 316,759.75
- Number of shares: 100,139
- Number of executions on buy side on semester: 993
- Number of executions on sell side on semester: 636
- Traded volume on buy side on semester: 152,845 shares for €
1,470,441.72
- Traded volume on sell side on semester: 98,168 shares for €
1,025,659.18
At the last half-year report as of December 31,
2021, the following resources were available in the liquidity
account:
- Cash: € 761,542.29
- Number of shares: 45,462
- Number of executions on buy side on semester: 1,253
- Number of executions on sell side on semester: 1,425
- Traded volume on buy side on semester: 209,935 shares for €
2,438,368.87
- Traded volume on sell side on semester: 211,076 shares for €
2,510,782.11
When the contract was initially implemented, the
following resources were included in the liquidity account:
- Cash: € 163,510.42
- Number of shares: 34,063
|
Buy Side |
|
Sell Side |
|
Number of executions |
Number of shares |
Traded volume in EUR |
|
Number of executions |
Number of shares |
Traded volume in EUR |
Total |
993 |
152,845 |
1,470,441.72 |
|
636 |
98,168 |
1,025,659.18 |
03/01/2022 |
8 |
1,000 |
11,800.00 |
|
12 |
2,471 |
29,553.16 |
04/01/2022 |
33 |
4,501 |
53,336.85 |
|
11 |
2,000 |
24,160.00 |
05/01/2022 |
20 |
1,950 |
22,542.00 |
|
2 |
500 |
5,850.00 |
06/01/2022 |
3 |
49 |
563.50 |
|
- |
- |
- |
07/01/2022 |
38 |
3,187 |
36,013.10 |
|
- |
- |
- |
10/01/2022 |
30 |
3,999 |
43,709.07 |
|
- |
- |
- |
11/01/2022 |
7 |
1,000 |
10,680.00 |
|
13 |
2,060 |
22,309.80 |
12/01/2022 |
12 |
2,000 |
22,160.00 |
|
9 |
3,440 |
38,872.00 |
13/01/2022 |
9 |
500 |
5,480.00 |
|
- |
- |
- |
14/01/2022 |
5 |
1,500 |
16,380.00 |
|
21 |
1,614 |
17,931.54 |
17/01/2022 |
2 |
1,000 |
10,980.00 |
|
7 |
639 |
7,099.29 |
19/01/2022 |
3 |
222 |
2,442.00 |
|
- |
- |
- |
20/01/2022 |
1 |
1 |
11.20 |
|
19 |
3,008 |
33,689.60 |
21/01/2022 |
8 |
1,234 |
13,771.44 |
|
6 |
203 |
2,285.78 |
24/01/2022 |
30 |
5,265 |
57,072.60 |
|
- |
- |
- |
25/01/2022 |
1 |
1 |
10.54 |
|
- |
- |
- |
26/01/2022 |
- |
- |
- |
|
8 |
1,500 |
16,125.00 |
27/01/2022 |
3 |
1,000 |
10,680.00 |
|
5 |
500 |
5,400.00 |
28/01/2022 |
8 |
1,319 |
14,179.25 |
|
17 |
2,537 |
27,627.93 |
31/01/2022 |
15 |
1,932 |
20,614.44 |
|
9 |
2,000 |
21,560.00 |
01/02/2022 |
- |
- |
- |
|
31 |
5,500 |
61,105.00 |
02/02/2022 |
- |
- |
- |
|
8 |
1,000 |
11,800.00 |
03/02/2022 |
10 |
2,000 |
22,720.00 |
|
11 |
827 |
9,436.07 |
04/02/2022 |
4 |
501 |
5,691.36 |
|
24 |
1,565 |
17,966.20 |
07/02/2022 |
3 |
500 |
5,750.00 |
|
9 |
2,000 |
23,340.00 |
08/02/2022 |
3 |
501 |
5,811.60 |
|
17 |
3,000 |
35,580.00 |
09/02/2022 |
7 |
1,501 |
17,666.77 |
|
16 |
1,500 |
17,880.00 |
10/02/2022 |
- |
- |
- |
|
1 |
50 |
598.00 |
11/02/2022 |
8 |
542 |
6,449.80 |
|
4 |
950 |
11,381.00 |
14/02/2022 |
27 |
4,852 |
56,380.24 |
|
- |
- |
- |
15/02/2022 |
4 |
500 |
5,530.00 |
|
- |
- |
- |
16/02/2022 |
4 |
500 |
5,550.00 |
|
3 |
501 |
5,641.26 |
17/02/2022 |
25 |
2,501 |
27,511.00 |
|
1 |
422 |
4,709.52 |
18/02/2022 |
4 |
1,000 |
10,860.00 |
|
12 |
2,185 |
23,947.60 |
21/02/2022 |
31 |
3,546 |
38,119.50 |
|
- |
- |
- |
22/02/2022 |
23 |
3,648 |
37,428.48 |
|
5 |
755 |
7,776.50 |
23/02/2022 |
- |
- |
- |
|
40 |
4,245 |
44,827.20 |
24/02/2022 |
31 |
5,306 |
53,272.24 |
|
2 |
155 |
1,612.00 |
|
Buy Side |
|
Sell Side |
|
|
Number of executions |
Number of shares |
Traded volume in EUR |
|
Number of executions |
Number of shares |
Traded volume in EUR |
|
Total |
993 |
152,845 |
1,470,441.72 |
|
636 |
98,168 |
1,025,659.18 |
|
25/02/2022 |
- |
- |
- |
|
36 |
4,345 |
45,622.50 |
|
28/02/2022 |
4 |
500 |
5,250.00 |
|
7 |
3,500 |
38,360.00 |
|
01/03/2022 |
6 |
1,749 |
19,169.04 |
|
10 |
2,109 |
23,768.43 |
|
02/03/2022 |
16 |
2,548 |
27,696.76 |
|
- |
- |
- |
|
03/03/2022 |
11 |
1,842 |
19,506.78 |
|
- |
- |
- |
|
04/03/2022 |
16 |
2,058 |
21,403.20 |
|
- |
- |
- |
|
07/03/2022 |
27 |
5,430 |
52,671.00 |
|
10 |
2,500 |
24,750.00 |
|
08/03/2022 |
5 |
1,501 |
14,964.97 |
|
8 |
2,501 |
25,760.30 |
|
09/03/2022 |
6 |
1,000 |
9,950.00 |
|
2 |
548 |
5,540.28 |
|
10/03/2022 |
- |
- |
- |
|
3 |
500 |
5,050.00 |
|
11/03/2022 |
6 |
1,000 |
9,950.00 |
|
- |
- |
- |
|
14/03/2022 |
4 |
1,500 |
15,060.00 |
|
6 |
500 |
5,050.00 |
|
15/03/2022 |
17 |
2,500 |
24,575.00 |
|
1 |
23 |
227.70 |
|
16/03/2022 |
6 |
500 |
5,000.00 |
|
11 |
1,977 |
19,849.08 |
|
17/03/2022 |
8 |
1,000 |
10,100.00 |
|
7 |
1,452 |
14,955.60 |
|
18/03/2022 |
4 |
500 |
5,050.00 |
|
1 |
94 |
958.80 |
|
21/03/2022 |
4 |
1,000 |
10,000.00 |
|
2 |
407 |
4,192.10 |
|
22/03/2022 |
5 |
251 |
2,530.08 |
|
14 |
1,999 |
20,409.79 |
|
23/03/2022 |
3 |
500 |
5,150.00 |
|
2 |
500 |
5,200.00 |
|
24/03/2022 |
6 |
500 |
5,100.00 |
|
- |
- |
- |
|
25/03/2022 |
12 |
926 |
9,454.46 |
|
2 |
260 |
2,678.00 |
|
28/03/2022 |
4 |
500 |
5,095.00 |
|
4 |
548 |
5,638.92 |
|
29/03/2022 |
2 |
501 |
5,110.20 |
|
14 |
2,457 |
25,307.10 |
|
30/03/2022 |
3 |
311 |
3,234.40 |
|
3 |
495 |
5,148.00 |
|
31/03/2022 |
11 |
542 |
5,631.38 |
|
- |
- |
- |
|
01/04/2022 |
8 |
1,234 |
12,685.52 |
|
- |
- |
- |
|
04/04/2022 |
5 |
598 |
6,099.60 |
|
6 |
1,000 |
10,320.00 |
|
05/04/2022 |
1 |
228 |
2,325.60 |
|
2 |
500 |
5,150.00 |
|
06/04/2022 |
1 |
137 |
1,397.40 |
|
1 |
6 |
61.80 |
|
07/04/2022 |
3 |
500 |
5,100.00 |
|
3 |
170 |
1,751.00 |
|
08/04/2022 |
5 |
473 |
4,777.30 |
|
2 |
2 |
20.40 |
|
11/04/2022 |
1 |
485 |
4,898.50 |
|
8 |
998 |
10,179.60 |
|
12/04/2022 |
10 |
1,000 |
10,150.00 |
|
3 |
867 |
8,886.75 |
|
13/04/2022 |
17 |
1,599 |
15,910.05 |
|
- |
- |
- |
|
14/04/2022 |
17 |
1,500 |
14,655.00 |
|
1 |
100 |
990.00 |
|
19/04/2022 |
- |
- |
- |
|
2 |
500 |
4,900.00 |
|
20/04/2022 |
1 |
1 |
9.70 |
|
20 |
1,500 |
14,850.00 |
|
21/04/2022 |
2 |
6 |
59.28 |
|
6 |
500 |
5,000.00 |
|
|
Buy Side |
|
Sell Side |
|
|
Number of executions |
Number of shares |
Traded volume in EUR |
|
Number of executions |
Number of shares |
Traded volume in EUR |
|
Total |
993 |
152,845 |
1,470,441.72 |
|
636 |
98,168 |
1,025,659.18 |
|
22/04/2022 |
5 |
495 |
4,900.50 |
|
- |
- |
- |
|
25/04/2022 |
20 |
1,782 |
17,231.94 |
|
1 |
7 |
69.30 |
|
26/04/2022 |
11 |
2,401 |
22,425.34 |
|
- |
- |
- |
|
27/04/2022 |
6 |
2,005 |
17,984.85 |
|
- |
- |
- |
|
28/04/2022 |
1 |
20 |
180.00 |
|
8 |
1,250 |
11,400.00 |
|
29/04/2022 |
- |
- |
- |
|
7 |
2,000 |
18,500.00 |
|
02/05/2022 |
4 |
500 |
4,600.00 |
|
11 |
550 |
5,120.50 |
|
03/05/2022 |
3 |
150 |
1,392.00 |
|
- |
- |
- |
|
05/05/2022 |
2 |
102 |
938.40 |
|
1 |
450 |
4,230.00 |
|
06/05/2022 |
6 |
898 |
8,315.48 |
|
- |
- |
- |
|
09/05/2022 |
14 |
1,980 |
17,919.00 |
|
- |
- |
- |
|
11/05/2022 |
10 |
2,544 |
22,387.20 |
|
9 |
1,316 |
11,962.44 |
|
12/05/2022 |
10 |
1,207 |
10,452.62 |
|
- |
- |
- |
|
13/05/2022 |
6 |
678 |
5,810.46 |
|
2 |
802 |
7,009.48 |
|
16/05/2022 |
8 |
1,291 |
10,973.50 |
|
- |
- |
- |
|
17/05/2022 |
4 |
1,012 |
8,551.40 |
|
7 |
1,500 |
12,900.00 |
|
18/05/2022 |
- |
- |
- |
|
9 |
1,131 |
10,031.97 |
|
19/05/2022 |
- |
- |
- |
|
5 |
619 |
5,614.33 |
|
20/05/2022 |
2 |
251 |
2,233.90 |
|
3 |
500 |
4,500.00 |
|
23/05/2022 |
3 |
1,499 |
13,341.10 |
|
4 |
250 |
2,262.50 |
|
24/05/2022 |
4 |
275 |
2,420.00 |
|
1 |
500 |
4,450.00 |
|
25/05/2022 |
- |
- |
- |
|
2 |
400 |
3,560.00 |
|
26/05/2022 |
1 |
500 |
4,450.00 |
|
3 |
500 |
4,500.00 |
|
27/05/2022 |
16 |
2,488 |
21,645.60 |
|
- |
- |
- |
|
30/05/2022 |
3 |
1,000 |
8,550.00 |
|
1 |
1 |
8.80 |
|
31/05/2022 |
7 |
750 |
6,435.00 |
|
3 |
849 |
7,386.30 |
|
01/06/2022 |
- |
- |
- |
|
4 |
500 |
4,300.00 |
|
02/06/2022 |
9 |
500 |
4,300.00 |
|
2 |
152 |
1,322.40 |
|
03/06/2022 |
15 |
1,200 |
10,224.00 |
|
2 |
149 |
1,296.30 |
|
06/06/2022 |
3 |
600 |
5,100.00 |
|
1 |
1 |
8.60 |
|
07/06/2022 |
1 |
1 |
8.51 |
|
3 |
189 |
1,625.40 |
|
08/06/2022 |
4 |
150 |
1,282.50 |
|
4 |
411 |
3,538.71 |
|
09/06/2022 |
3 |
655 |
5,619.90 |
|
- |
- |
- |
|
10/06/2022 |
8 |
845 |
7,233.20 |
|
3 |
500 |
4,350.00 |
|
13/06/2022 |
21 |
2,488 |
20,501.12 |
|
- |
- |
- |
|
14/06/2022 |
21 |
4,100 |
32,267.00 |
|
- |
- |
- |
|
15/06/2022 |
5 |
1,500 |
11,220.00 |
|
- |
- |
- |
|
16/06/2022 |
10 |
3,000 |
21,540.00 |
|
- |
- |
- |
|
|
Buy Side |
|
Sell Side |
|
|
Number of executions |
Number of shares |
Traded volume in EUR |
|
Number of executions |
Number of shares |
Traded volume in EUR |
|
Total |
993 |
152,845 |
1,470,441.72 |
|
636 |
98,168 |
1,025,659.18 |
|
17/06/2022 |
3 |
1,000 |
7,000.00 |
|
1 |
500 |
3,600.00 |
|
20/06/2022 |
7 |
1,000 |
7,000.00 |
|
3 |
971 |
6,942.65 |
|
21/06/2022 |
1 |
500 |
3,550.00 |
|
3 |
180 |
1,299.60 |
|
22/06/2022 |
16 |
4,500 |
30,375.00 |
|
1 |
500 |
3,500.00 |
|
23/06/2022 |
8 |
1,000 |
6,650.00 |
|
- |
- |
- |
|
24/06/2022 |
- |
- |
- |
|
5 |
500 |
3,350.00 |
|
27/06/2022 |
10 |
2,000 |
12,960.00 |
|
4 |
500 |
3,400.00 |
|
28/06/2022 |
7 |
2,500 |
15,325.00 |
|
1 |
1 |
6.50 |
|
29/06/2022 |
18 |
6,000 |
34,260.00 |
|
1 |
500 |
2,950.00 |
|
30/06/2022 |
- |
- |
- |
|
1 |
4 |
22.80 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
About Inventiva
Inventiva is a clinical-stage biopharmaceutical
company focused on the research and development of oral small
molecule therapies for the treatment of NASH and other diseases
with significant unmet medical need. The Company benefits from a
strong expertise and experience in the domain of compounds
targeting nuclear receptors, transcription factors and epigenetic
modulation. Inventiva’s lead product candidate, lanifibranor, is
currently in a pivotal Phase III clinical trial, NATiV3, for the
treatment of adult patients with NASH, a common and progressive
chronic liver disease for which there are currently no approved
therapies.
The Company has established a strategic
collaboration with AbbVie in the area of autoimmune diseases that
resulted in the discovery of the drug candidate cedirogant
(ABBV-157), an oral RORγ inverse agonist which is being evaluated
in a Phase IIb clinical trial, led by AbbVie, in adult patients
with moderate to severe chronic plaque psoriasis. Inventiva’s
pipeline also includes odiparcil, a drug candidate for the
treatment of adult mucopolysaccharidoses (MPS) VI patients. As part
of Inventiva’s decision to focus clinical efforts on the
development of lanifibranor, it suspended clinical efforts relating
to odiparcil and is reviewing available options with respect to its
potential further development. Inventiva is in the process of
selecting an oncology development candidate for its Hippo signaling
pathway program.
The Company has a scientific team of
approximately 80 people with deep expertise in the fields of
biology, medicinal and computational chemistry, pharmacokinetics
and pharmacology, and clinical development. It owns an extensive
library of approximately 240,000 pharmacologically relevant
molecules, approximately 60% of which are proprietary, as well as a
wholly-owned research and development facility.
Inventiva is a public company listed on
compartment C of the regulated market of Euronext Paris (ticker:
IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the
United States (ticker: IVA). www.inventivapharma.com.
Contacts
InventivaPascaline ClercVP of Global External
Affairsmedia@inventivapharma.com +1 240 620 9175 |
Brunswick GroupTristan Roquet Montegon / Aude
Lepreux / Matthieu BenoistMedia
relationsinventiva@brunswickgroup.com+33 1 53 96 83 83 |
Westwicke, an ICR CompanyPatricia L. BankInvestor
relations patti.bank@westwicke.com+1 415 513 1284 |
Important Notice
This press release contains “forward-looking
statements” within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical facts, included in this press
release are forward-looking statements. These statements include,
but are not limited to, forecasts and estimates with respect to
Inventiva’s pre-clinical programs and clinical trials, including
recruitment, screening and enrolment for those trials,
including LEGEND, clinical trial data releases and publications,
the information, insights and impacts that may be gathered from
clinical trials, including LEGEND, the potential therapeutic
benefits of lanifibranor in combination with empagliflozin, the
design of trials, including LEGEND, pipeline and preclinical
and clinical development plans, milestone payments, royalties and
product sales, future activities, expectations, plans, growth and
prospects of Inventiva and the sufficiency of Inventiva’s cash
resources and cash runway. Certain of these statements, forecasts
and estimates can be recognized by the use of words such as,
without limitation, “believes”, “anticipates”, “expects”,
“intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “would”,
“could”, “might”, “should”, “plans”, “designed”, “hopefully” and
“continue” and similar expressions. Such statements are not
historical facts but rather are statements of future expectations
and other forward-looking statements that are based on management's
beliefs. These statements reflect such views and assumptions
prevailing as of the date of the statements and involve known and
unknown risks and uncertainties that could cause future results,
performance or future events to differ materially from those
expressed or implied in such statements. Future events are
difficult to predict and may depend upon factors that are beyond
Inventiva's control. There can be no guarantees with respect to
pipeline product candidates that the clinical trial results will be
available on their anticipated timeline, that future clinical
trials will be initiated as anticipated, that product candidates
will receive the necessary regulatory approvals, or that any of the
anticipated milestones by Inventiva or its partners will be reached
on their expected timeline, or at all. Actual results may turn out
to be materially different from the anticipated future results,
performance or achievements expressed or implied by such
statements, forecasts and estimates, due to a number of factors,
including that Inventiva is a clinical-stage company with no
approved products and no historical product revenues, Inventiva has
incurred significant losses since inception, Inventiva has a
limited operating history and has never generated any revenue from
product sales, Inventiva will require additional capital to finance
its operations, Inventiva's future success is dependent on the
successful clinical development, regulatory approval and subsequent
commercialization of current and any future product candidates,
preclinical studies or earlier clinical trials are not necessarily
predictive of future results and the results of Inventiva's
clinical trials may not support Inventiva's product candidate
claims, Inventiva may encounter substantial delays in its clinical
trials or Inventiva may fail to demonstrate safety and efficacy to
the satisfaction of applicable regulatory authorities, enrolment
and retention of patients in clinical trials is an expensive and
time-consuming process and could be made more difficult or rendered
impossible by multiple factors outside Inventiva's control,
Inventiva's product candidates may cause adverse drug reactions or
have other properties that could delay or prevent their regulatory
approval, or limit their commercial potential, Inventiva faces
substantial competition and Inventiva’s business, and preclinical
studies and clinical development programs and timelines, its
financial condition and results of operations could be materially
and adversely affected by the current COVID-19 pandemic and
geopolitical events, such as the conflict between Russia and
Ukraine and related impacts and potential impacts on the
initiation, enrolment and completion of Inventiva’s clinical trials
on anticipated timelines. Given these risks and uncertainties, no
representations are made as to the accuracy or fairness of such
forward-looking statements, forecasts and estimates. Furthermore,
forward-looking statements, forecasts and estimates only speak as
of the date of this press release. Readers are cautioned not to
place undue reliance on any of these forward-looking
statements.
Please refer to the Universal Registration
Document for the year ended December 31, 2021 filed with the
Autorité des Marchés Financiers on March 11, 2022 and the Annual
Report on Form 20-F for the year ended December 31, 2021 filed with
the Securities and Exchange Commission on March 11, 2022 for
additional information in relation to such factors, risks and
uncertainties.
All information in this press release is as of
the date of the release. Except as required by law, Inventiva has
no intention and is under no obligation to update or review the
forward-looking statements referred to above.
- Inventiva - PR - Liquidity Contract - S1 22 - EN - 21 07
2022
Inventiva (EU:IVA)
Historical Stock Chart
From May 2024 to Jun 2024
Inventiva (EU:IVA)
Historical Stock Chart
From Jun 2023 to Jun 2024